M
Monique L. den Boer
Researcher at Boston Children's Hospital
Publications - 115
Citations - 7234
Monique L. den Boer is an academic researcher from Boston Children's Hospital. The author has contributed to research in topics: Acute lymphocytic leukemia & Leukemia. The author has an hindex of 40, co-authored 107 publications receiving 6466 citations. Previous affiliations of Monique L. den Boer include Erasmus University Medical Center & Erasmus University Rotterdam.
Papers
More filters
Journal ArticleDOI
A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study
Monique L. den Boer,Marjon van Slegtenhorst,Renee X. de Menezes,Renee X. de Menezes,Meyling Cheok,Jessica Buijs-Gladdines,Susan T C J M Peters,Laura J. C. M. van Zutven,H. Berna Beverloo,Peter J. van der Spek,Gaby Escherich,Martin A. Horstmann,Gritta Janka-Schaub,Willem A. Kamps,William E. Evans,Rob Pieters +15 more
TL;DR: A genome-wide study to improve prognostic classification of ALL in children revealed a new ALL subtype, the underlying genetic abnormalities of which were characterised by comparative genomic hybridisation-arrays and molecular cytogenetics.
Journal ArticleDOI
Gene-Expression Patterns in Drug-Resistant Acute Lymphoblastic Leukemia Cells and Response to Treatment
Amy Holleman,Meyling Cheok,Monique L. den Boer,Wenjian Yang,Anjo J.P. Veerman,Karin M. Kazemier,Deqing Pei,Cheng Cheng,Ching-Hon Pui,Mary V. Relling,Gritta Janka-Schaub,Rob Pieters,William E. Evans +12 more
TL;DR: Differential expression of a relatively small number of genes is associated with drug resistance and treatment outcome in childhood ALL.
Journal ArticleDOI
Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance
Guo Wei,Guo Wei,David Twomey,David Twomey,Justin Lamb,Krysta D. Schlis,Jyoti Agarwal,Ronald W. Stam,Joseph T. Opferman,Stephen E. Sallan,Monique L. den Boer,Rob Pieters,Todd R. Golub,Scott A. Armstrong +13 more
TL;DR: Data indicate that MCL1 is an important regulator of GC-induced apoptosis and that the combination of rapamycin and glucocorticoids has potential utility in lymphoid malignancies.
Journal ArticleDOI
Inhibition of FLT3 in MLL: Validation of a therapeutic target identified by gene expression based classification
Scott A. Armstrong,Andrew L. Kung,Andrew L. Kung,Meghann E. Mabon,Lewis B. Silverman,Lewis B. Silverman,Ronald W. Stam,Monique L. den Boer,Rob Pieters,John H. Kersey,Stephen E. Sallan,Stephen E. Sallan,Jonathan A. Fletcher,Todd R. Golub,Todd R. Golub,Todd R. Golub,James D. Griffin,James D. Griffin,Stanley J. Korsmeyer,Stanley J. Korsmeyer +19 more
TL;DR: A mouse model of MLL is developed and bioluminescent imaging is used to determine that PKC412 is active against MLL in vivo and proves cytotoxic to Ba/F3 cells dependent upon activated FLT3 containing either mutation.
Journal ArticleDOI
Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL.
Arian van der Veer,Esmé Waanders,Rob Pieters,Marieke E. Willemse,Simon V. van Reijmersdal,Lisa J. Russell,Christine J. Harrison,William E. Evans,Vincent H.J. van der Velden,Peter M. Hoogerbrugge,Frank N. van Leeuwen,Gabriele Escherich,Martin A. Horstmann,Leila Mohammadi Khankahdani,Dimitris Rizopoulos,Hester A. de Groot-Kruseman,Edwin Sonneveld,Roland P. Kuiper,Monique L. den Boer +18 more
TL;DR: The BCR-ABL1-like signature and an IKZF1 deletion, but not CRLF2-high, are prognostic factors and are clinically of importance to identify high-risk patients who require more intensive and/or alternative therapies.